SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, Yoshimoto M, Miura-Okuda M, Uchikawa R, Kato C, Shinozuka J, Akai S, Naoi S, Tomioka N, Nagaya N, Pang CL, Garvita G, Feng S, Shimada M, Kamata-Sakurai M, Aburatani H, Kitazawa T, Igawa T.
Kamikawa T, et al. Among authors: kitazawa t.
J Immunother Cancer. 2024 Oct 14;12(10):e009563. doi: 10.1136/jitc-2024-009563.
J Immunother Cancer. 2024.
PMID: 39401967
Free PMC article.